Drugs / Loncastuximab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06977711 | Jun 2025 → Oct 2026 expected | diffuse large B-cell lymphoma | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Loncastuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06977711 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4297238 ↗ |
| Route | Intravenous | “Intravenous (IV) administration 0.15 mg/kg day 1 cycles 1-2, and 0.075mg/kg day 1, cycles 3-5” NCT06977711 ↗ |